Drug intelligence / Profile preview

Renshen Fuling Decoction

Development stage: Unknown
Lead developer: The Second Affiliated Hospital of Zhejiang Chinese Medical University
Administration: Oral

Overview

Renshen Fuling Decoction is a traditional Chinese medicine (TCM) herbal formula being evaluated for the treatment of severe SARS-CoV-2 infection (COVID-19). The decoction, which primarily consists of *Panax ginseng* (Renshen) and *Poria cocos* (Fuling), is being studied in clinical trials sponsored by The Second Affiliated Hospital of Zhejiang Chinese Medical University to determine its efficacy in reducing all-cause mortality and the rate of progression to critical illness. In traditional practice, these components are utilized to tonify vital energy (Qi) and regulate fluid metabolism, which may help counteract the systemic inflammation and immune exhaustion characteristic of severe viral pneumonia.

Other names: Renshen Fuling Tang人参茯苓汤

Beyond the preview

Go deeper on Renshen Fuling Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renshen Fuling Decoction.

Explore the full profile